These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. Minari R; Leonetti A; Gnetti L; Zielli T; Ventura L; Bottarelli L; Lagrasta C; La Monica S; Petronini PG; Alfieri R; Tiseo M Anticancer Drugs; 2021 Aug; 32(7):758-762. PubMed ID: 33675607 [TBL] [Abstract][Full Text] [Related]
6. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. Lee K; Kim D; Yoon S; Lee DH; Kim SW Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716 [TBL] [Abstract][Full Text] [Related]
7. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138 [TBL] [Abstract][Full Text] [Related]
8. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Hochmair MJ; Morabito A; Hao D; Yang CT; Soo RA; Yang JC; Gucalp R; Halmos B; Wang L; Golembesky A; Märten A; Cufer T Future Oncol; 2018 Nov; 14(27):2861-2874. PubMed ID: 30336693 [TBL] [Abstract][Full Text] [Related]
9. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539 [TBL] [Abstract][Full Text] [Related]
10. Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells. Yonesaka K; Kobayashi Y; Hayashi H; Chiba Y; Mitsudomi T; Nakagawa K Oncol Rep; 2019 Feb; 41(2):1059-1066. PubMed ID: 30483795 [TBL] [Abstract][Full Text] [Related]
11. Acquired T790M-positive Squamous Cell Lung Carcinoma that Responded to Osimertinib. Yamasaki M; Funaishi K; Daido W; Hattori N Arch Bronconeumol (Engl Ed); 2019 Nov; 55(11):602-603. PubMed ID: 31122852 [No Abstract] [Full Text] [Related]
12. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. Nakamura T; Nakashima C; Komiya K; Kitera K; Hirai M; Kimura S; Aragane N PLoS One; 2018; 13(12):e0209384. PubMed ID: 30550608 [TBL] [Abstract][Full Text] [Related]
13. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib. Yamamoto N; Mera T; Märten A; Hochmair MJ Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283 [TBL] [Abstract][Full Text] [Related]
15. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465 [TBL] [Abstract][Full Text] [Related]
16. Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations. Ikari T; Sakakibara-Konishi J; Yamamoto G; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N Clin Lung Cancer; 2019 Jul; 20(4):e531-e533. PubMed ID: 31164318 [No Abstract] [Full Text] [Related]
17. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib. Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113 [TBL] [Abstract][Full Text] [Related]
18. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment. Yang Y; Liu Q; Cao L; Sun W; Gu X; Liu B; Xiao N; Teng F; Li X; Chen M; Yu W; Lin H; Xu G BMC Pulm Med; 2021 May; 21(1):172. PubMed ID: 34011336 [TBL] [Abstract][Full Text] [Related]
19. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
20. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]